[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Current guidelines suggest limiting diagnostic testing for chronic spontaneous urticaria when no clear cause is suspected, though biomarkers and biopsies are emerging as tools to predict treatment ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss ...

Biologics, including medications like mepolizumab and dupilumab, are widely prescribed for patients with severe asthma and ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...